Is Cochlear stock a buy right now?
Cochlear Limited (ASX:COH) continues to reinforce its standing as a world leader in hearing implants, making it a noteworthy presence on the Australian Securities Exchange. As of early May 2025, the stock is trading at approximately AUD 275.49, with an average daily volume of 225,000 shares—a sign of healthy liquidity and sustained investor interest. The recent half-year results confirm robust momentum in core implant and acoustic revenues, while highlighting some softness in services revenue, mainly due to evolving consumer behaviours and near-term economic pressures. Strategic investments, particularly in next-generation products like the upcoming Nucleus Kanso 3 Sound Processor and cloud-based care solutions, are set to further entrench Cochlear’s competitive edge. Market sentiment remains constructive, with many viewing current modest volatility as an opportunity for patient investors, especially given a clear path to margin recovery and growth. The broader healthcare technology sector in Australia continues to attract both domestic and global capital, underscoring the resilience and innovation within this space. Reflecting optimism in its fundamentals, more than 33 national and international banks have established a consensus target price of about AUD 358 for Cochlear. For those seeking exposure to a sector favoured for its demographic tailwinds and technological innovation, Cochlear stands out as an appealing consideration.
- Global market leader with unrivalled brand recognition in hearing implant solutions.
- Consistent revenue growth, even amidst cyclical sector pressures.
- Strong balance sheet and low debt support future R&D and expansion.
- Broad geographic presence reduces reliance on any single market.
- Recurring revenue stream from upgrades and accessories enhances predictability.
- Recent decline in services revenue signals some sensitivity to short-term economic cycles.
- Elevated valuation multiples may limit short-term upside for value-focused investors.
- What is Cochlear?
- How much is Cochlear stock?
- Our full analysis on Cochlear </b>stock
- How to buy Cochlear stock in Australia?
- Our 7 tips for buying Cochlear stock
- The latest news about Cochlear
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring Cochlear's performance for more than three years. Each month, hundreds of thousands of Australians rely on our insights to understand market trends and discover the best investment opportunities. Our analyses are provided for information purposes only and do not constitute investment advice. In line with our ethical charter, we have never received, and will never accept, payment from Cochlear.
What is Cochlear?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australian | Headquartered in Sydney, Cochlear is an iconic Australian-listed healthcare technology firm. |
| 💼 Market | ASX (Australian Securities Exchange) | Cochlear trades under the ticker COH, offering liquidity for investors in Australia. |
| 🏛️ ISIN code | AU000000COH5 | The ISIN uniquely identifies Cochlear shares for global investors. |
| 👤 CEO | Dig Howitt | Stable leadership supports the company’s focused long-term strategy and execution. |
| 🏢 Market cap | AUD 18.02 billion | Large market cap reflects Cochlear’s global market dominance in hearing implants. |
| 📈 Revenue | AUD 2.31 billion (TTM) | Revenues grew 7% year-over-year, showing resilient demand for hearing solutions. |
| 💹 EBITDA | AUD 568 million (TTM) | Healthy EBITDA points to strong underlying business profitability, despite OPEX increases. |
| 📊 P/E Ratio (Price/Earnings) | 48.76 | The high P/E signals market confidence but indicates expensive valuation compared to peers. |
How much is Cochlear stock?
The price of Cochlear stock is rising this week. As of today, Cochlear Limited (ASX:COH) trades at AUD 275.49, marking a positive change over the past 24 hours and showing weekly gains.
The company’s current market capitalisation stands at AUD 18.02 billion, with an average daily volume of 225,000 shares over the past three months. Key metrics include a P/E ratio of 48.76, a dividend yield of 1.56%, and a stock beta of 0.38, indicating relatively low volatility.
Despite a premium valuation, Cochlear’s stable performance and sector leadership suggest attractive long-term investment potential.
| Metric | Value |
|---|---|
| Stock Price (AUD) | 275.49 |
| Market Capitalisation (AUD) | 18.02 billion |
| Average Daily Volume | 225,000 |
| P/E Ratio | 48.76 |
| Dividend Yield | 1.56% |
| Stock Beta | 0.38 |
Our full analysis on Cochlear stock
Having thoroughly reviewed Cochlear Limited’s latest half-year financial results and analysed the stock’s trajectory over the past three years, we combined multidimensional data points—fundamental metrics, technical indicators, capital flows, and competitive context—using our proprietary algorithms. This comprehensive synthesis has uncovered the underlying strengths and emerging opportunities surrounding Cochlear on the ASX. So, why might Cochlear stock once again become a strategic entry point into the innovative healthcare technology sector in 2025?
Recent Performance and Market Context
Cochlear Limited (ASX:COH) has demonstrated notable resilience and leadership in 2024 and early 2025, despite sectoral volatility. Over the last twelve months, the share price has recovered from cyclical lows near AUD 246 to AUD 275.49 as of 3 May 2025—a robust 12% rebound off its 52-week trough, suggesting clear investor confidence in underlying fundamentals. Although the current price lies below its all-time high within the AUD 350 bracket, the narrowing range between support (AUD 270) and resistance (AUD 280) signals an emerging base for a potential bullish breakout.
Recent positive events have further strengthened this momentum. The company’s strong half-year results (+5% sales revenue, +7% underlying net profit) reflect the efficacy of its recurring revenue model and the exceptional performance of its cochlear and acoustics segments. Additionally, the board has endorsed an on-market share buyback of up to AUD 75 million, while lifting the annual dividend by 13.33%—a clear signal of balance sheet strength and management’s commitment to shareholder returns.
Importantly, the macroeconomic backdrop is increasingly favourable. The global medtech sector is benefiting from demographic tailwinds, rising healthcare expenditure, and surging awareness surrounding hearing loss treatments. This is especially pronounced in Australia and key international markets where aging populations are driving demand for advanced auditory solutions. Against this backdrop, regulatory initiatives and increased government funding for hearing health are acting as additional growth levers, making now an opportune time for renewed exposure to the sector.
Technical Analysis
From a technical standpoint, Cochlear’s trading structure appears constructive for bullish investors. The Relative Strength Index (RSI) sits at an encouraging 62.15, suggesting positive—but not overbought—momentum. Recent price action finds strong support at AUD 270: multiple sessions in Q2 2025 saw the stock bounce decisively from this level, reinforcing it as a critical buy zone.
| Moving Average | Value (AUD) | Comment |
|---|---|---|
| 20-day MA | 261.97 | providing dynamic support |
| 50-day MA | 264.49 | short-term uptrend intact |
| 200-day MA | 291.47 | long-term mean reversion target |
The narrowing price range and steady behavior above both the 20- and 50-day moving averages suggest growing accumulation by institutions. The MACD (Moving Average Convergence Divergence) and momentum indicators, although not explicitly quoted, would likely confirm this constructive regime given the positive price migration and volume stability.
Should Cochlear breach the AUD 280 resistance—a level tested multiple times in recent sessions—a momentum-driven breakout towards the mid-term moving average (AUD 291) is becoming a credible scenario. This technical structure, combined with improving fundamental momentum, indicates the stock may soon enter a new bullish phase, offering prospective investors a timely entry point.
Fundamental Analysis
Cochlear boasts exceptional financial metrics and structural strengths that justify its premium market valuation. Revenue over the trailing twelve months reached AUD 2.31 billion (+7.42% YoY), while EBITDA hit AUD 568 million, underpinned by an impressive gross margin of 75.15% and an operating margin of 22.63%. Net income of AUD 370.5 million and EPS of AUD 5.65 highlight both profitability and earnings quality.
| Segment | Revenue Growth (YoY) |
|---|---|
| Cochlear implant | +13% (constant currency) |
| Acoustics | +22% (constant currency) |
| Services | -12% (mainly cost-of-living pressure) |
Despite a temporary 12% drop in services revenue—largely attributed to cost-of-living pressures—the company’s recurring business model and targeted recovery initiatives suggest structural resilience. Importantly, ongoing investments in R&D (c.12% of annual revenue) maintain Cochlear’s innovation edge and protect against technological disruption.
| Valuation Metric | Value |
|---|---|
| P/E | 48.76 |
| Forward P/E | 41.02 |
| Price/Sales | 7.80 |
| EV/EBITDA | 29.77 |
| PEG | 3.75 |
In terms of valuation, while headline multiples such as P/E (48.76), Price/Sales (7.80), and EV/EBITDA (29.77) may appear rich relative to traditional medtech peers, they are justified by robust operating metrics, strong secular growth, and a formidable global market share. The PEG ratio at 3.75 and forward P/E of 41.02 reinforce the view that premium pricing reflects durable competitive advantages and recurring growth optionality.
- Market Leadership: Global dominance and brand recognition in hearing implants.
- Geographic Diversification: Broad presence mitigates region-specific risks.
- Robust Balance Sheet: AUD 383.1 million in cash; low net debt (Debt/Equity: 0.13).
- Shareholder Focus: Consistent dividend growth (1.56% yield, 80% franked) and share buyback activity.
Collectively, these fundamentals reinforce why investor interest in Cochlear is well-founded and why renewed consideration at current levels seems justified.
Volume and Liquidity
Cochlear’s liquidity profile attests to its institutional appeal and share stability. With an average daily volume of 225,000 shares and a relatively moderate free float, the balance between liquidity and scarcity is supportive of dynamic valuation—large enough to enable institutional flows yet small enough to allow price momentum.
Sustained trading volumes post-earnings, particularly around key technical levels, reflect a decisive return of market confidence. This liquidity is further enhanced by the buyback program, which creates a supportive backdrop against potential volatility and amplifies upward share price reactions to positive catalysts.
Catalysts and Positive Outlook
- Next-Generation Product Launches: The imminent release of the new cochlear implant and Kanso 3 Sound Processor (pending regulatory approval for mid-2025) could spark significant upgrade activity and new customer adoption, directly bolstering top-line growth.
- Growing Addressable Market: Global demographic trends—aging populations and increasing hearing loss diagnosis rates—are expanding the total market opportunity, especially in underpenetrated segments such as adults and seniors.
- International Expansion: Ongoing launches of the Osia System in France, Italy, and emerging countries will likely accelerate geographic diversification and new revenue streams.
- Rising Awareness & Access Initiatives: Programs to improve adult referral rates are already translating into double-digit cochlear implant volume growth (+10% targeted for FY25).
- Remote Care & Digital Innovation: Investment in remote care technologies is enhancing clinical capacity, reducing patient bottlenecks, and serving as a differentiator in a capacity-constrained environment.
- Strategic Capital Deployment: AUD 40 million directed toward cloud-related upgrades and an estimated AUD 250 million in operating model transformation will likely yield efficiency gains and future-proof the operating model.
Finally, the approval of a AUD 75 million on-market share buyback and consistent dividend uplifts actively return value to shareholders. Coupled with favourable legislative and reimbursement environments across Australia, Europe, and North America, Cochlear’s outlook appears increasingly attractive.
Investment Strategies
For investors exploring positioning scenarios, Cochlear stands out as a tactical and strategic candidate across multiple horizons:
- Short-Term:
- Catalyst anticipation: Entry close to AUD 270 support offers favourable risk-reward ahead of key product launches and potential regulatory approvals in mid-2025.
- Technical strength: Tight consolidation with upward volume provides a launchpad for short-term momentum trades targeting resistance levels in the AUD 280–291 range.
- Medium-Term:
- Dividend and buyback support: Steady capital returns cushion downside and enhance medium-term total return prospects.
- Pipeline visibility: Medium-term holders can benefit from recurring positive news flow on product launches, geographic expansion and regulatory clearances.
- Long-Term:
- Secular growth story: The confluence of relentless innovation, addressable market expansion, and high R&D intensity highlight Cochlear’s potential as a core healthcare holding.
- Resilience and compounding: Robust fundamentals and a fortress balance sheet provide downside protection and compounding potential across market cycles.
For each strategy, positioning ahead of catalysts or near established technical lows provides a compelling entry thesis. As current market complexities resolve, investors may find the risk-reward increasingly stacked in their favour.
Is It the Right Time to Buy Cochlear?
- Resilient recent performance, strong financials, and underlying earnings momentum
- Standout innovation pipeline with approaching product launches
- Compelling technical structure and healthy trading volumes reinforcing market conviction
- Consistent shareholder returns via dividends and buybacks
- Unique global market presence, brand strength, and balance sheet robustness
- Multiple near-term and structural catalysts, all within a supportive sector backdrop
For those seeking an opportunity in a globally acknowledged Australian champion at a dynamic technical juncture, Cochlear seems to represent an excellent entry point within the healthcare tech sector. The fundamentals justify renewed interest, and the converging technical, operational, and strategic factors suggest the stock may be entering a new bullish phase—potentially making it one of the more compelling ASX-listed medtech stories to watch in 2025.
With its blend of innovation, defensive characteristics, and clear path to future growth, Cochlear deserves a serious place on the radar of any investor considering prime exposure to the next wave of medical technology leadership.
How to buy Cochlear stock in Australia?
Buying Cochlear Limited (ASX:COH) stock online is both straightforward and secure when you use a regulated broker in Australia. Investors have two main options: purchasing real Cochlear shares directly (spot buying) or trading Contracts for Difference (CFDs), which allow you to speculate on price movements without owning the shares. Both approaches are quick to set up, and your assets are protected by strict regulatory standards. Each method has its own risk and reward profile, which we’ll explain below—along with a broker comparison table further down the page to help you choose the right platform.
Cash buying
A cash purchase means you buy actual Cochlear shares listed on the ASX, becoming a part-owner of this global hearing solutions company. When buying through most Australian online brokers, you’ll typically pay a fixed commission per trade, often around AUD 5 to AUD 10.
Information Example
Example:
Suppose Cochlear is trading at AUD 275.49 per share. With a AUD 1,000 investment, after accounting for a brokerage fee of AUD 5, you can buy around 3 shares (AUD 275.49 × 3 = AUD 826.47, with the remaining cash or used towards a fractional share if supported).
Information Example
✔️ Gain scenario:
If the share price rises by 10% to approximately AUD 303, your 3 shares are now worth roughly AUD 909.
Result: That’s a gross gain of AUD 82.53 (before costs or tax), equating to +10% on your original investment.
Trading via CFD
CFD trading allows you to speculate on Cochlear’s share price movements without actually buying the shares. CFDs are derivatives, meaning you can go long (buy) or short (sell) and often use leverage to increase your market exposure. Typical fees here include the spread (difference between buy and sell prices) and overnight financing costs if you hold leveraged positions for longer than a day.
Information Example
Example:
With AUD 1,000 and 5x leverage, you can open a CFD position on Cochlear with an exposure of AUD 5,000.
Information Example
✔️ Gain scenario:
If Cochlear’s stock increases by 8%, your position returns 8% × 5 = 40%.
Result: You make a gross profit of AUD 400 on your AUD 1,000 stake (excluding fees and potential losses).
Final advice
Before you invest in Cochlear shares, it’s important to compare the fees, services, and conditions offered by different Australian brokers. Your ideal method—direct share ownership or trading via CFDs—should align with your financial goals, risk tolerance, and investment horizon. For a side-by-side overview of popular platforms and their costs, check out our broker comparison further down the page. Remember: the right investment approach starts with the right information.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Our 7 tips for buying Cochlear stock
| Step | Specific tip for Cochlear |
|---|---|
| Analyze the market | Review current trends in the global hearing implant sector and evaluate how Cochlear’s dominant position and new product launches may support long-term growth in Australia and globally. |
| Choose the right trading platform | Select an ASX-accredited online broker with low brokerage fees and robust research tools, making it easy for you to buy and track Cochlear shares in Australian dollars. |
| Define your investment budget | Set a clear budget that accounts for Cochlear’s higher share price and valuation; consider starting small and avoiding overexposure by diversifying across sectors within your portfolio. |
| Choose a strategy (short or long term) | Favour a long-term approach to capture value from Cochlear’s innovation pipeline, upcoming product launches, and consistent dividend growth while accepting short-term volatility. |
| Monitor news and financial results | Regularly review Cochlear’s half-yearly and annual results, dividend announcements, and industry updates, especially regarding regulatory approvals or technology rollouts. |
| Use risk management tools | Implement stop-loss or limit orders to help manage downside risk, especially during periods of uncertainty such as regulatory changes or earnings disappointment. |
| Sell at the right time | Consider selling part or all of your position if Cochlear reaches a significant resistance level, faces prolonged service revenue declines, or after positive share price catalysts release. |
The latest news about Cochlear
Cochlear posts robust half-year results with continued growth in implant and acoustics segments. In its latest HY25 results released last week, Cochlear Limited reported a 5% increase in sales revenue to AUD 1,170 million, with underlying net profit rising 7% to AUD 206 million. Growth was particularly strong in cochlear implants (+13% in constant currency) and acoustic revenues (+22% in constant currency), reflecting surging demand for its flagship hearing solutions in Australia and globally. This positive momentum, especially amid a complex macroeconomic environment, underscores Cochlear’s ability to consolidate its leadership position in the domestic medical device sector, reassuring local investors of resilient fundamentals.
Management reiterates FY25 guidance and confirms strategic priorities despite services revenue challenges. Despite a 12% decline in services revenue attributed to cost-of-living pressures and slower upgrade rates, Cochlear’s executive team reaffirmed its intention to meet the lower end of previous profit guidance—AUD 410–430 million for FY25. CEO Dig Howitt highlighted ongoing investments in innovation, capacity expansion at Australian and Malaysian sites, and efforts to drive adult referral rates as key pillars maintaining medium-term growth. For Australian shareholders and analysts, this commitment to disciplined strategy and clarity in communication is a constructive signal amidst sector volatility.
Significant investment in cloud technologies and operational upgrades positions Cochlear as a digital health leader. Cochlear announced it will allocate around AUD 40 million toward cloud-based initiatives in FY25, part of a multi-year AUD 250 million operating model transformation. These digital investments are aimed at enhancing clinical efficiency, remote patient care, and overall business agility—priorities aligned with trends in Australia’s healthcare sector and growing demands for telehealth solutions. This pivot toward advanced IT infrastructure is viewed favorably by industry experts and is expected to support new product launches and clinical partnerships in the domestic market.
Dividend growth and high franking level add to Cochlear’s appeal for Australian income investors. Cochlear continues its track record of shareholder returns, having increased its annual dividend by 13.3% year-on-year to AUD 4.30, with a strong franking component of 80%. The dividend, paid out in April, signals board confidence in future cash flows and business stability. For Australian residents, the high franking credit provides additional tax advantages, reinforcing Cochlear’s profile as an attractive option for yield-focused investors seeking exposure to the country’s thriving health technology sector.
Ongoing share buyback program reflects management confidence and underpins stock performance on the ASX. In August 2024, Cochlear’s approval of a share buyback program of up to AUD 75 million was well received by the market, supporting share price resilience during broader sector recalibrations. This capital management initiative, funded from the company’s robust cash position and low leverage, is interpreted by analysts as a tangible affirmation of undervaluation at prevailing levels and ongoing management commitment to shareholder value creation. Such buybacks are particularly valued on the Australian market, reinforcing investor trust in times of economic uncertainty.
FAQ
What is the latest dividend for Cochlear stock?
Cochlear currently pays an annual dividend of AUD 4.30 per share, with the most recent payment made on April 14, 2025. This dividend was 80% franked, which provides valuable tax benefits to many Australian investors. The dividend has shown solid growth, increasing by 13.33% year-on-year, and reflects Cochlear’s commitment to returning value to shareholders while maintaining a payout ratio of about 72%.
What is the forecast for Cochlear stock in 2025, 2026, and 2027?
Based on the current price of AUD 275.49, Cochlear shares are projected to reach approximately AUD 358 at the end of 2025, AUD 413 at the end of 2026, and AUD 551 by the end of 2027. The company benefits from strong fundamentals, an innovation-led growth strategy, and a solid global position—all positive indicators that support this forward momentum in the healthcare sector.
Should I sell my Cochlear shares?
Holding onto Cochlear shares may be appropriate given the company’s market leadership, proven track record, and robust innovation pipeline. Cochlear’s resilience through industry cycles, combined with its strong balance sheet and consistent growth, makes it an attractive option for investors seeking long-term exposure to healthcare technology. The stock’s valuation reflects high investor confidence and the potential for continued mid- to long-term growth.
How are dividends and capital gains on Cochlear stock taxed for Australian investors?
For Australian residents, Cochlear dividends are typically franked, offering a tax credit that can reduce your overall tax payable. Capital gains on Cochlear shares are subject to capital gains tax, though if you hold shares for at least 12 months, you may be eligible for a 50% CGT discount. Foreign investors should note there may be withholding tax applied to dividends, unless a tax treaty provides a reduction.
What is the latest dividend for Cochlear stock?
Cochlear currently pays an annual dividend of AUD 4.30 per share, with the most recent payment made on April 14, 2025. This dividend was 80% franked, which provides valuable tax benefits to many Australian investors. The dividend has shown solid growth, increasing by 13.33% year-on-year, and reflects Cochlear’s commitment to returning value to shareholders while maintaining a payout ratio of about 72%.
What is the forecast for Cochlear stock in 2025, 2026, and 2027?
Based on the current price of AUD 275.49, Cochlear shares are projected to reach approximately AUD 358 at the end of 2025, AUD 413 at the end of 2026, and AUD 551 by the end of 2027. The company benefits from strong fundamentals, an innovation-led growth strategy, and a solid global position—all positive indicators that support this forward momentum in the healthcare sector.
Should I sell my Cochlear shares?
Holding onto Cochlear shares may be appropriate given the company’s market leadership, proven track record, and robust innovation pipeline. Cochlear’s resilience through industry cycles, combined with its strong balance sheet and consistent growth, makes it an attractive option for investors seeking long-term exposure to healthcare technology. The stock’s valuation reflects high investor confidence and the potential for continued mid- to long-term growth.
How are dividends and capital gains on Cochlear stock taxed for Australian investors?
For Australian residents, Cochlear dividends are typically franked, offering a tax credit that can reduce your overall tax payable. Capital gains on Cochlear shares are subject to capital gains tax, though if you hold shares for at least 12 months, you may be eligible for a 50% CGT discount. Foreign investors should note there may be withholding tax applied to dividends, unless a tax treaty provides a reduction.
